Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aslan Pharmaceuticals Ltd ADR
(NQ:
ASLN
)
0.6000
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aslan Pharmaceuticals Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
March 27, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
March 16, 2024
BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug...
Via
Talk Markets
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
March 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
March 11, 2024
Via
Benzinga
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
March 11, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 06, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
March 06, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
February 29, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
February 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 12, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
January 08, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
January 02, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 15, 2023
Via
Benzinga
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
December 12, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 04, 2023
Via
Benzinga
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
November 03, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 27, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
October 13, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
3 Stocks to Sell Ahead of the Coming VIX Spike
September 26, 2023
As the VIX's cycle begins to creep upward, investors would be wise to bail on these stocks to sell before their volatility destroys returns.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
September 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 11, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
